本文選題：身材偏矮　切入點：中藥及營養(yǎng)　出處：《山東中醫(yī)藥大學(xué)》2012年碩士論文　論文類型：學(xué)位論文

【摘要】：目的：本課題旨在觀察中藥及營養(yǎng)、運(yùn)動處方綜合干預(yù)骨齡正常和偏大的身材偏矮兒童的臨床療效；比較此綜合干預(yù)法與重組人生長激素的優(yōu)越性。 方法：選取骨齡正常和偏大的身材偏矮兒童219例，隨機(jī)分為干預(yù)1組、干預(yù)2組、空白對照組，各組再根據(jù)骨齡分為三個年齡段：6~11歲骨齡、~15歲骨齡、~18歲骨齡。 干預(yù)1組給予中藥及營養(yǎng)、運(yùn)動處方綜合干預(yù)，干預(yù)2組給予國產(chǎn)r-hGH治療，空白對照組未進(jìn)行任何治療和干預(yù)，，療程為12個月。治療前及療程結(jié)束后分別檢測兒童身高、體重、骨齡，療程結(jié)束后計算年生長速度、骨成熟變化情況、費(fèi)用。采用單因素方差分析、獨立樣本t檢驗統(tǒng)計學(xué)方法分析后比較三組治療12個月后的身高、體重、骨齡、年生長速率、骨成熟變化情況，比較干預(yù)1組中骨齡正常與骨齡偏大兒童12個月后身高、年生長速度的變化；比較干預(yù)1組與干預(yù)2組的治療費(fèi)用情況；比較三組兒童發(fā)展為矮小癥的比率。 結(jié)果：1.干預(yù)1組與空白對照組12月后的身高有顯著性差異（P0.05），6~11歲骨齡身高分別為：138.27±7.43cm、132.63±6.29cm；~15歲骨齡身高分別為：152.60±7.60cm、148.92±7.12cm；~18歲骨齡身高分別為：162.83±7.02cm、159.25±5.69cm。 2.干預(yù)1組、干預(yù)2組、空白對照組三組身高年生長速率比較有顯著性差異（P0.05），6~11歲骨齡分別為：9.86±1.41、7.00±0.85、4.80±0.75；~15歲骨齡分別為：8.18±2.55、6.90±2.00、4.46±1.36；~18歲骨齡分別為：4.69±1.81、3.40±0.87、2.15±0.85。 3.干預(yù)1組、干預(yù)2組、對照組治療后體重、骨齡、骨成熟變化情況無顯著性差異（P0.05）。 4.干預(yù)1組中骨齡正常兒童身高年生長速率（7.93±2.64cm/年）與骨齡偏大兒童年生長速率（4.90±2.80cm/年）有顯著行差異（P0.05）。 5.干預(yù)1組與干預(yù)2組治療12個月后總費(fèi)用比較有顯著性差異（P0.05）。 6.干預(yù)1組、干預(yù)2組12個月后未發(fā)現(xiàn)矮小癥兒童，空白對照組發(fā)現(xiàn)6例發(fā)展為矮小癥。 結(jié)論：中藥及營養(yǎng)、運(yùn)動處方綜合干預(yù)骨齡正常和偏大的身材偏矮兒童臨床療效顯著，效果優(yōu)于重組人生長激素；中藥及營養(yǎng)、運(yùn)動處方綜合干預(yù)對骨齡正常的身材矮小兒童效果更佳。中藥及營養(yǎng)、運(yùn)動處方綜合干預(yù)12個月的費(fèi)用明顯低于重組人生長激素治療的同期費(fèi)用。如果對身材偏矮兒童不進(jìn)行任何干預(yù)和治療，部分偏矮兒童將發(fā)展為矮小癥。
[Abstract]:Objective: the purpose of this study is to observe the clinical efficacy of Chinese medicine and nutrition and exercise prescription intervention in children with normal bone age and too short stature, and compare the superiority of this comprehensive intervention and recombinant human growth hormone.
Methods: 219 children with normal bone age and larger body size were selected and randomly divided into intervention group 1, intervention group 2, blank control group. According to bone age, each group was divided into three age groups: 6~11 years old bone age, ~15 years old bone age, ~18 age bone age.
1 the intervention group was treated with Chinese medicine and nutrition, exercise prescription intervention, intervention group received 2 domestic r-hGH treatment, control group without any treatment and intervention treatment for 12 months. Before and after treatment were detected in children's height, weight, bone age, after the end of treatment to calculate the annual growth rate, bone maturation changes cost, by ANOVA, independent samples t test analysis method were compared between the three groups after 12 months after treatment the height, weight, age, growth rate, bone maturation changes, compared 1 groups of normal bone age and bone age of children is 12 months after the height of intervention, changes in growth speed; intervention between 1 group and 2 group intervention treatment costs; the ratio between the three groups for the development of children of short stature.
Results: 1. 1 intervention group and blank control group in December after the height had significant difference (P0.05), 6~11 years old age height were: 138.27 + 7.43cm, 132.63 + 6.29cm; ~15 years old age height were: 152.60 + 7.60cm, 148.92 + 7.12cm; ~18 years old age height were: 162.83 + 7.02cm, 159.25 + 5.69cm.
2. intervention group 1, group 2, control group three group height growth rate had significant difference (P0.05), 6~11 years old age were: 9.86 + 1.41,7.00 + 0.85,4.80 + 0.75; ~15 years old age were: 8.18 + 2.55,6.90 + 2.00,4.46 + 1.36; ~18 years old age were: 4.69 + 1.81,3.40 + 0.87,2.15 + 0.85.
3. intervention in 1 groups, intervention in 2 groups, the control group after treatment weight, bone age, bone maturity, no significant difference (P0.05).
4. intervention in 1 groups, the growth rate of body height (7.93 + 2.64cm/ years) in skeletal age normal children was significantly different from that in skeletal age children (4.90 + 2.80cm/ years) (P0.05).
There was a significant difference in total cost between the 1 groups in the 5. intervention group and the intervention of the 2 groups for 12 months (P0.05).
6. the 1 groups were intervened and the children were not found short of dwarfism after 12 months of intervention. The blank control group found 6 cases developed into dwarfism.
Conclusion: the traditional Chinese medicine and nutrition, exercise prescription intervention bone age normal and too large short stature children's curative effect is better than that of recombinant human growth hormone; traditional Chinese medicine and better nutrition, exercise prescription intervention on bone age normal children with short stature. The effect of traditional Chinese medicine and nutrition, exercise prescription intervention costs over the same period of 12 months was significantly lower than that of recombinant human growth hormone treatment. If the short stature children without any intervention and treatment, the partial short of children will be developed for short stature.

【學(xué)位授予單位】：山東中醫(yī)藥大學(xué)
【學(xué)位級別】：碩士
【學(xué)位授予年份】：2012
【分類號】：R725.8

【參考文獻(xiàn)】

相關(guān)期刊論文 前10條

1 陳小平;李海浪;鄭意楠;;滋陰瀉火中藥為主治療女性特發(fā)性性早熟的臨床分析[J];中國當(dāng)代兒科雜志;2007年03期

2 趙小媛;林濤;李秀珍;吳冬燕;;矮小兒童生長激素與全血微量元素水平分析[J];廣東醫(yī)學(xué);2010年20期

3 李樹欽;;營養(yǎng)素缺乏對兒童生長發(fā)育的影響及預(yù)防對策[J];國際醫(yī)藥衛(wèi)生導(dǎo)報;2006年01期

4 羅佐杰,冼蘇,梁淡媚,韋敏怡,陸焯平,李春靈,彭崇基;高健美治療正常兒童青少年矮身材的臨床研究[J];廣西醫(yī)學(xué);1999年01期

5 董治亞;王偉;杜曉飛;崔貽芬;奚容平;王德芬;;人生長激素同型異構(gòu)體比例變化與特發(fā)性矮小癥的相關(guān)性[J];臨床兒科雜志;2006年12期

6 王凡;錢尚統(tǒng);顧勤;;補(bǔ)益肝腎法為主對青少年身高生長的臨床研究[J];遼寧中醫(yī)雜志;2007年08期

7 朱升朝,孫敬方,于利群,馬艷,戴平,林艷麗;按摩促進(jìn)嬰幼兒生長發(fā)育的機(jī)理及實驗研究[J];南京中醫(yī)藥大學(xué)學(xué)報(自然科學(xué)版);2002年01期

8 張茵頎,劉戌年;基因重組生長激素治療特發(fā)性矮小研究進(jìn)展[J];國外醫(yī)學(xué).婦幼保健分冊;2004年03期

9 俞建;吳家敏;楊毅;汪永紅;時毓民;周文江;朱列偉;;抗早熟中藥對青春發(fā)育啟動大鼠骨骼生長及相關(guān)基因的影響[J];上海中醫(yī)藥大學(xué)學(xué)報;2006年01期

10 黃誠,秦秀娣,周羚,方軍,劉劍,陳漢平;針灸調(diào)節(jié)老年大鼠垂體激素分泌[J];上海針灸雜志;1997年04期

相關(guān)博士學(xué)位論文 前1條

1 房冬梅;運(yùn)動對雌性大鼠長骨生長的影響及其基因表達(dá)譜特征研究[D];蘇州大學(xué);2007年

相關(guān)碩士學(xué)位論文 前1條

1 劉少蘭;足三里穴為主健脾按摩法對嬰兒生長發(fā)育干預(yù)的研究[D];廣州中醫(yī)藥大學(xué);2011年

本文編號：1556586